NASDAQ:STLN
Starling Oncology, Inc.
Starling Oncology, Inc.'s revenue grew 27.8% in fiscal 2025 to $502.7M while operating margin rose to −7.2%. Free cash flow was −$27.8M, −5.5% of revenue, and the diluted share count rose 23.1%.Summary generated from Starling Oncology, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$502.7M
Revenue growth+27.8%
Revenue, 5-yr CAGR+21.8%
Gross marginn/a
Operating margin−7.2%
Net margin−12.1%
ROIC−75.8%
Return on equityn/a
Debt / equityn/a
Free cash flow−$27.8M
FCF margin−5.5%
Share count change+23.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 203 | 252 | 324 | 393 | 503 |
| Operating income | −46 | −82 | −77 | −60 | −36 |
| Net income | −11 | 0 | −83 | −65 | −61 |
| Free cash flow | −36 | −67 | −41 | −30 | −28 |
Recent filings
- 8-KDirector or officer change
Sep 2, 2026 - 4Insider transaction report
Aug 24, 2026 - 8-KEntry into a material agreement
Aug 21, 2026 - 4Insider transaction report
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KAmendment to articles or bylaws
Aug 3, 2026 - 8-KEntry into a material agreement
Jul 7, 2026